Accuray

Accuray Incorporated is a radiation oncology company that designs, develops, and sells advanced radiosurgery and radiation therapy systems for tumor treatment across various regions, including the Americas, Europe, the Middle East, India, Japan, Africa, and the Asia Pacific. The company's flagship product, the CyberKnife System, is a robotic platform that delivers precise radiation therapy by automatically tracking and correcting for patient and tumor movement in real-time. This system allows for high doses of radiation to be administered while patients breathe normally, enhancing treatment effectiveness. Accuray also offers the TomoTherapy System, including the Radixact System, which provides versatile radiation therapy solutions for diverse cancer types. The company markets its products directly in the United States and through distributors and sales agents in international markets, targeting hospitals and standalone treatment centers. Established in 1990 and headquartered in Sunnyvale, California, Accuray aims to improve cancer treatment outcomes by providing innovative technologies and solutions that enhance treatment precision and efficiency.

Andrew Kirkpatrick

COO and Senior Vice President

2 past transactions

Morphormics

Acquisition in 2012
Morphormics Inc., also known as Mx, develops medical imaging software for auto-segmentation of organs and structures. Its technology provides near-automatic segmentation of organs in CT and other images for radiation treatment planning, and other clinical and research uses. The company offers MxStruct software that segments anatomical structures for radiotherapy and radiosurgery treatment planning. Its MxStruct is used for male pelvis auto-segmentation for the prostate cancer treatment planning. The company was founded in 2001 and is based in Chapel Hill, North Carolina.

TomoTherapy

Acquisition in 2011
TomoTherapy develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy:registered: platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its Hi·Art:registered: treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD:tm: treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile:tm: relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. As of February 2011, there are more than 350 TomoTherapy systems in use in 24 countries worldwide. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.